DoD Prostate Cancer, Idea Development Award | W81XWH 22 PCRP IDA

Opportunity Information: Apply for W81XWH 22 PCRP IDA

The Department of Defense (DoD), through the Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program (PCRP), offered the FY22 Idea Development Award (Funding Opportunity Number W81XWH-22-PCRP-IDA) to fund bold, genuinely new prostate cancer research concepts that could meaningfully advance the PCRP mission. The program is designed for projects that move beyond incremental follow-ons to published work and instead introduce fresh approaches, new frameworks, or creative uses of data, methods, and populations. Multidisciplinary projects and data science-driven strategies are explicitly encouraged, especially when they bring new perspectives to long-standing problems in prostate cancer biology, prevention, diagnosis, or treatment.

A central expectation is that proposals clearly connect innovation to impact. Applicants must address at least one of the FY22 PCRP Overarching Challenges and explain, in practical terms, how the work could produce near-term and longer-term benefits for prostate cancer research and/or patient care. In other words, novelty by itself is not enough; reviewers are looking for ideas that, if they work, would shift the field in a noticeable way or open up new paths toward better outcomes for patients.

Unlike many other mechanisms, preliminary data are encouraged but not required, which lowers the barrier for high-risk, high-reward ideas. If applicants do include unpublished preliminary data, it needs to come from the PI or members of the research team. Even without pilot results, the application still has to stand on solid scientific reasoning supported by a strong rationale and careful engagement with the existing literature. To strengthen reproducibility and translational relevance, applicants are urged to build in good research hygiene where it fits the work, including cell line authentication, strong statistical practices in animal and epidemiologic studies, steps that demonstrate clinical relevance, and validation in patient cohorts when feasible. If the project depends on specialized resources (datasets, specimens, platforms, cohorts, or institutional capabilities), letters of support documenting access and availability are strongly recommended.

The opportunity includes a dedicated New Investigator category meant to bring in early-career faculty or investigators who are still establishing independence. New Investigator applications are reviewed with different personnel criteria, and they must include at least one collaborator with demonstrated prostate cancer expertise, reflected in prior funding and publications. The proposal needs to spell out why the collaboration is likely to work, what each partner contributes, and how the partnership strengthens the science and the PI’s ability to execute the project. Letters of collaboration are strongly encouraged to make the working relationship concrete rather than aspirational.

Team science is welcomed, including multi-institutional collaborations, but the DoD expects applicants to show they can actually operate as a coordinated unit. Multi-institutional projects must include a clear interaction plan covering communication, coordination of progress and results, and data transfer. They also must include an intellectual property plan to reduce friction around ownership and sharing of ideas and materials, with the goal of preventing institutional barriers from undermining collaboration.

Human subjects research is allowed, but clinical trials are not. The program draws a bright line around trials by defining them as studies where human subjects are prospectively assigned to interventions to measure outcomes. However, the announcement encourages correlative studies linked to existing clinical trials, which can be a strong fit when investigators can leverage ongoing trial infrastructure without running a new trial under this award. For any prospective clinical research that involves human subjects, risk must be no greater than minimal risk as determined by the relevant IRB and by the USAMRDC Office of Research Protections Human Research Protection Office (HRPO). Importantly, local IRB approval is not required at the time of application submission, but DoD HRPO review and approval is required before research can begin, and applicants are advised to plan for the regulatory timeline (often up to about three months once a complete package is submitted). If more than one institution is involved in human subjects research, a written single-IRB plan is required, identifying the lead institution responsible for the master protocol and consent and serving as the central regulatory point of contact.

Animal work is permitted, but it carries an additional DoD oversight step. Beyond the local IACUC, studies involving animals must be reviewed by the USAMRDC Animal Care and Use Review Office (ACURO). As with HRPO, IACUC approval is not required at submission, but applicants should account for the additional review time (often three to four months). Across preclinical work, the program emphasizes rigorous design and transparent reporting aligned with widely accepted standards such as the principles highlighted by Landis et al. (randomization, blinding, sample-size estimation, and clear data handling) and the ARRIVE 2.0 guidelines for in vivo animal research.

From an administrative and funding standpoint, awards are issued as assistance agreements, meaning they may be structured as either a grant or a cooperative agreement. The deciding factor is the anticipated level of DoD involvement during performance; projects that require substantial federal involvement (such as active collaboration, participation, or intervention) may be issued as cooperative agreements, whereas projects with minimal agency involvement are more likely to be funded as grants. The anticipated direct cost cap for the full period of performance is up to $900,000. The DoD projected funding of roughly $44.64 million total to support approximately 31 awards, with awards expected to be made by September 30, 2023, and FY22 funds expected to remain available for use through September 30, 2028, subject to federal funding availability and standard review outcomes.

The announcement also stresses mission relevance to active-duty Service Members, Veterans, military beneficiaries, and the broader American public, and it encourages partnerships between military or VA institutions and non-military organizations to leverage unique patient populations, infrastructure, and expertise. Applicants are pointed to recommendations from the congressionally mandated Metastatic Cancer Task Force and encouraged to align ideas with those translational and clinical acceleration priorities when consistent with this mechanism’s rules (notably the prohibition on running clinical trials under the award).

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 04, 2022.
• Applicants must submit their applications by Jul 28, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 31 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: